/PRNewswire/ Exact Sciences Corp. (NASDAQ: EXAS), a leading provider of cancer screening and diagnostic tests, today announced late-breaking data from the.
Phase 3 Data Analysis Presented at EADV 2023 Showed Bimekizumab Achieved High Thresholds of Clinical Response in Hidradenitis SuppurativaBimekizumab treatment resulted in clinically meaningful improvements in HiSCR50 and the more stringent endpoints HiSCR75, HiSCR90 and HiSCR100 vs. placebo at Week 16, with improvem.
The findings from these 2 trials for bimekizumab may lead to greater treatment options for patients with HS, an often debilitating and chronic skin condition.